Aikido Pharma Inc AIKI:NASDAQ

Set AlertOptionsStreaming Charts
Earnings Announcement Next Earnings date is expected on 05/17/2022
Last Price$0.33NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22

Today's Change+0.03(9.09%)
Bid (Size)$0.32 (5)
Ask (Size)$0.33 (160)
Day Low / High$0.30 - 0.34
Volume2.2 M
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Biotechnology IndustryPeer Comparison as of 05/13/2022

Timeframe
 

Aikido Pharma Inc ( NASDAQ )

Price: $0.33
Change: +0.03 (9.09%)
Volume: 2.2 M
4:00PM ET 5/13/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Marker Therapeutics Inc ( NASDAQ )

Price: $0.33
Change: +0.02 (4.90%)
Volume: 524.0 K
4:00PM ET 5/13/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Aravive Inc ( NASDAQ )

Price: $1.10
Change: -0.02 (1.79%)
Volume: 65.6 K
3:59PM ET 5/13/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Caladrius Biosciences Inc ( NASDAQ )

Price: $0.44
Change: +0.03 (8.22%)
Volume: 231.4 K
3:55PM ET 5/13/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Chemomab Therapeutics Ltd ( NASDAQ )

Price: $2.79
Change: +0.21 (8.14%)
Volume: 23.6 K
3:55PM ET 5/13/2022
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

AIkido Pharma Enters Master Collaboration Agreement With Cedars-Sinai Medical Center
2:26PM ET 3/08/2022 MT Newswires

AIkido Pharma (AIKI) said Tuesday that it entered a master collaboration agreement with Cedars-Sinai Medical Center, a non-profit academic healthcare...

AIkido Secures New US Patent for Pancreatic Cancer Drug, Reports New Manufacturing Process
11:13AM ET 3/03/2022 MT Newswires

AIkido Pharma (AIKI) said Thursday it secured an additional US patent covering claims for its pancreatic cancer drug DHA-dFdC. The new patent is valid...

AIkido Pharma Closes $22 Million Registered Direct Offering
3:11AM ET 3/03/2022 MT Newswires

AIkido Pharma Inc. closed its previously announced registered direct offering with certain institutional investors of 11,000 shares of Series O and 11,000...

AIkido Pharma to Raise $20.9 Million in Net Proceeds Via Registered Direct Offering; Shares Decline
10:16AM ET 2/25/2022 MT Newswires

AIkido Pharma (AIKI) on Friday launched a registered direct offering to raise approximately $20.9 million in net proceeds. The biotechnology company...

View all Commentary and Analysis

AIkido Pharma: Advancing Anticancer And Antiviral Therapies
12:26PM ET 2/10/2022 Seeking Alpha

Company Profile

Business DescriptionAIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY. View company web site for more details
AddressOne Rockefeller Plaza
New York, New York 10020
Phone+1.12.745.1374
Number of Employees6
Recent SEC Filing05/04/20224
CEO, Chief Financial Officer & DirectorAnthony C. Hayes

Company Highlights

Price Open$0.30
Previous Close$0.30
52 Week Range$0.29 - 1.21
Market Capitalization$29.3 M
Shares Outstanding89.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement05/17/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.10
Beta vs. S&P 500N/A
Revenue$28.0 K
Net Profit MarginN/A
Return on Equity-6.96%

Analyst Ratings as of 04/06/2022

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset